Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds
Authors:
- Madeline KimMKMadeline Kim
- Ester Del DucaEDEster Del Duca
- Dante DahabrehDDDante Dahabreh
- Daniel Lozano‐OjalvoDLDaniel Lozano‐Ojalvo
- Britta CarrollBCBritta Carroll
- Meredith MansonMMMeredith Manson
- Swaroop BoseSBSwaroop Bose
- Digpal GourDGDigpal Gour
- Monali NandyMazumdarMNMonali NandyMazumdar
- Ying LiuYLYing Liu
- Mitchelle Yu EkeyMEMitchelle Yu Ekey
- Amira ChowdhuryACAmira Chowdhury
Abstract
Background: Alopecia areata (AA) is a chronic, nonscarring hair‐loss disorder associated with significant quality‐of‐life impairment and limited treatment options. AA has been recently linked to atopy and shown to exhibit both Th1‐ and Th2‐driven inflammation. However, a comprehensive molecular and cellular characterization across blood and scalp compartments in both atopic and nonatopic patients is lacking.Methods: Lesional and nonlesional scalp biopsies obtained from AA patients with (n = 16) or without (n = 20) atopic history, and 17 demographically matched healthy controls were analyzed with RNA‐seq, RT‐PCR, and immunohistochemistry. Flow cytometry was also performed on peripheral blood mononuclear cells (PBMCs) from a subset of patients. Differential expression was defined using |fold‐change| > 1.5 and false‐discovery rate IFNG, CXCL9, CXCL10, CXCL11) and Th2‐related products (CCL26, CCR4, IL10, IL13, TSLP, TNFRSF4/OX40) and shared downregulation of hair keratins, regardless of atopic background, with variable Th17/Th22 modulation. AA patients with atopy exhibited greater inflammatory tone and Th2‐skewing (IL10, IL13, IL33, CCR4, CCL26). Disease severity correlated significantly with immune and hair keratin biomarkers and with perifollicular cellular infiltrates. Cutaneous OX40/OX40L upregulation was paralleled by increases in circulating OX40+ and OX40L+ leukocytes, regardless of atopic background.Conclusion: Our results suggest some atopy‐associated immune differences in AA and highlight the OX40 axis as a potential novel therapeutic target that may broadly benefit AA patients.Keywords
Funding Information
- Kyowa Kirin Pharmaceutical Development
- National Center for Advancing Translational Sciences
This publication has 73 references indexed in Scilit:
- Associations between season, climate, and pediatric alopecia areata flares in Providence, Rhode IslandArchives of Dermatological Research, 2023
- Baricitinib for the Treatment of Alopecia AreataDrugs, 2023
- Critical role of OX40/OX40L in ILC2-mediated activation of CD4+T cells during respiratory syncytial virus infection in miceInternational Immunopharmacology, 2019
- Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuationAnnals of Allergy, Asthma & Immunology, 2019
- Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid CellsImmunity, 2018
- Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With Alopecia Areata in the United StatesJAMA Dermatology, 2013
- IL-15/IL-15 receptor biology: A guided tour through an expanding universeCytokine & Growth Factor Reviews, 2006
- Functional characterization of OX40 expressed on human CD8+ T cellsImmunology Letters, 2006
- Familial aggregation of alopecia areataJournal of the American Academy of Dermatology, 2006
- Alopecia areata investigational assessment guidelines–Part IIJournal of the American Academy of Dermatology, 2004